Indication
NMIBC
5 clinical trials
7 products
Product
ZH9Clinical trial
A Phase 1/1b Study Evaluating the Safety, Pharmacology, and Clinical Effect of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder CancerStatus: Recruiting, Estimated PCD: 2025-02-03
Product
UGN-301Clinical trial
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBCStatus: Recruiting, Estimated PCD: 2025-12-01
Product
UGN-201Product
GemcitabineProduct
Enfortumab vedotinClinical trial
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)Status: Recruiting, Estimated PCD: 2024-06-30
Product
RC48-ADCClinical trial
An Open-label, Single Arm, Single Center Phase 2 Study of RC48-ADC (IV) in Combination With Gemcitabine(Intravesical) in High Risk NMIBC Subjects (BCG Naïve or BCG Unresponsive) That Expresses HER2 (IHC 1+ and Greater)Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase 2 Window of Opportunity Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk TumorsStatus: Recruiting, Estimated PCD: 2024-05-01
Product
Pemigatinib